Matza LS - Search Results

1

Health state utilities associated with weight loss in type 2 diabetes and obesity.

Boye KS, Matza LS, Stewart KD, Andrews H, Howell TA, Stefanski A, Malley KG, Ishak KJ, Fernández Landó L. Boye KS, et al. Among authors: matza ls. J Med Econ. 2022 Jan-Dec;25(1):14-25. doi: 10.1080/13696998.2021.2002062. J Med Econ. 2022. PMID: 34734554 Free article.

2

Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom.

Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S. Secnik K, et al. Among authors: matza ls. Med Decis Making. 2005 Jan-Feb;25(1):56-70. doi: 10.1177/0272989X04273140. Med Decis Making. 2005. PMID: 15673582

3

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.

Secnik Boye K, Matza LS, Oglesby A, Malley K, Kim S, Hayes RP, Brodows R. Secnik Boye K, et al. Among authors: matza ls. Health Qual Life Outcomes. 2006 Oct 11;4:80. doi: 10.1186/1477-7525-4-80. Health Qual Life Outcomes. 2006. PMID: 17034640 Free PMC article. Clinical Trial.

4

Utilities and disutilities for type 2 diabetes treatment-related attributes.

Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, Barber BL. Matza LS, et al. Qual Life Res. 2007 Sep;16(7):1251-65. doi: 10.1007/s11136-007-9226-0. Epub 2007 Jul 19. Qual Life Res. 2007. PMID: 17638121

5

Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change.

Matza LS, Yurgin N, Boye KS, Malley K, Shorr JM. Matza LS, et al. Curr Med Res Opin. 2007 Sep;23(9):2051-62. doi: 10.1185/030079907X219454. Curr Med Res Opin. 2007. PMID: 17651535

6

Validation of two generic patient-reported outcome measures in patients with type 2 diabetes.

Matza LS, Boye KS, Yurgin N. Matza LS, et al. Health Qual Life Outcomes. 2007 Jul 31;5:47. doi: 10.1186/1477-7525-5-47. Health Qual Life Outcomes. 2007. PMID: 17672906 Free PMC article.

7

Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL).

Matza LS, Johnston JA, Faries DE, Malley KG, Brod M. Matza LS, et al. Qual Life Res. 2007 Nov;16(9):1511-20. doi: 10.1007/s11136-007-9254-9. Epub 2007 Sep 12. Qual Life Res. 2007. PMID: 17874207 Clinical Trial.

8

The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy.

Matza LS, Rousculp MD, Malley K, Boye KS, Oglesby A. Matza LS, et al. Health Qual Life Outcomes. 2008 Nov 7;6:95. doi: 10.1186/1477-7525-6-95. Health Qual Life Outcomes. 2008. PMID: 18992161 Free PMC article. Clinical Trial.

9

Derivation and validation of the ASK-12 adherence barrier survey.

Matza LS, Park J, Coyne KS, Skinner EP, Malley KG, Wolever RQ. Matza LS, et al. Ann Pharmacother. 2009 Oct;43(10):1621-30. doi: 10.1345/aph.1M174. Epub 2009 Sep 23. Ann Pharmacother. 2009. PMID: 19776298

10

Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.

Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Boye KS, et al. Among authors: matza ls. Eur J Health Econ. 2011 Jun;12(3):219-30. doi: 10.1007/s10198-010-0224-8. Epub 2010 Mar 12. Eur J Health Econ. 2011. PMID: 20224930

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

109 results

Search Page

Filters